Nitric oxide and the endothelium: History and impact on cardiovascular disease

Vascular Pharmacology

Volumn 45, Issue 5, 2006, Pages 268-276

  Yetik Anacak, Gunay ^a   Catravas, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cardiovascular disease; Endothelium; Nitric oxide

Indexed keywords

ANTIOXIDANT; ARGININE; CALMODULIN; CARDIO DISCOVERY; CAVEOLIN; CITRULLINE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELDANAMYCIN; GLUTAMINE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEART BAR; HEAT SHOCK PROTEIN 90; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; NATURAL PRODUCT; NITEWORKS; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NOXTREME; OXODROL; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; RADICICOL; SCAFFOLD PROTEIN; SILDENAFIL; TETRAHYDROBIOPTERIN; VITAMIN;

ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; ERECTILE DYSFUNCTION; ETHNOLOGY; FAMILY HISTORY; GENE THERAPY; HUMAN; HYPERTENSION; MALNUTRITION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; HISTORY, 20TH CENTURY; HOMEOSTASIS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION;

EID: 33751104760     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.08.002     Document Type: Article

References (95)

1. Adams M.R., Jessup W., and Celermajer D.S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral l-arginine but not vitamin C. J. Am. Coll. Cardiol. 29 (1997) 491-497
2. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321 (2001) 225-236
3. Amant C., Hamon M., Bauters C., Richard F., Helbecque N., McFadden E.P., Escudero X., Lablanche J.M., Amouyel P., and Bertrand M.E. The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J. Am. Coll. Cardiol. 29 (1997) 486-490
4. Andersson K., Gaudiot N., Ribiere C., Elizalde M., Giudicelli Y., and Arner P. A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo. Br. J. Pharmacol. 126 (1999) 1639-1645
5. Baek K.J., Thiel B.A., Lucas S., and Stuehr D.J. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J. Biol. Chem. 268 (1993) 21120-21129
6. Barua R.S., Ambrose J.A., Saha D.C., and Eales-Reynolds L.J. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 106 (2002) 905-908
7. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol., Cell Physiol. 271 (1996) C1424-C1437
8. Bender A.T., Silverstein A.M., Demady D.R., Kanelakis K.C., Noguchi S., Pratt W.B., and Osawa Y. Neuronal nitric-oxide synthase is regulated by the hsp90-based chaperone system in vivo. J. Biol. Chem. 274 (1999) 1472-1478
9. Billecke S.S., Bender A.T., Kanelakis K.C., Murphy P.J.M., Lowe E.R., Kamada Y., Pratt W.B., and Osawa Y. hsp90 is required for heme binding and activation of Apo-neuronal nitric-oxide synthase. Geldanamycin-mediated oxidant generation is unrelated to any action of hsp90. J. Biol. Chem. 277 (2002) 20504-20509
10. Boulanger C., and Luscher T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85 (1990) 587-590
11. Bredt D.S., and Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 682-685
12. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J. Biol. Chem. 276 (2001) 32663-32669
13. Bucci M., Roviezzo F., Cicala C., Sessa W.C., and Cirino G. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br. J. Pharmacol. 131 (2000) 13-16
14. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.-P., Arvieler D., Luc G., Bard J.-M., Bara L., Richard S., Tiret L., Amouyel P., Alhenc-Gelas F., and Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359 (1992) 641-644
15. Campisi R., Czernin J., Schoder H., Sayre J.W., and Schelbert H.R. l-Arginine normalizes coronary vasomotion in long-term smokers. Circulation 99 (1999) 491-497
16. Cao S., Yao J., McCabe T.J., Yao Q., Katusic Z.S., Sessa W.C., and Shah V. Direct interaction between endothelial nitric-oxide synthase and dynamin-2. Implications for nitric-oxide synthase function. J. Biol. Chem. 276 (2001) 14249-14256
17. Catravas J.D., Lazo J.S., Dobuler K.J., Mills L.R., and Gillis C.N. Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am. Rev. Respir. Dis. 128 (1983) 740-746
18. Chauhan A., More R.S., Mullins P.A., Taylor G., Petch C., and Schofield P.M. Aging-associated endothelial dysfunction in humans is reversed by l-arginine. J. Am. Coll. Cardiol. 28 (1996) 1796-1804
19. Chen P.Y., and Sanders P.W. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 22 (1993) 812-818
20. Cooke J.P., Singer A.H., Tsao P., Zera P., Rowan R.A., and Billingham M.E. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 90 (1992) 1168-1172
21. Corson M.A., James N.L., Latta S.E., Nerem R.M., Berk B.C., and Harrison D.G. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ. Res. 79 (1996) 984-991
22. Creager M.A., Gallagher S.J., Girerd X.J., Coleman S.M., Dzau V.J., and Cooke J.P. l-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90 (1992) 1248-1253
23. Dawson T.M., and Snyder S.H. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J. Neurosci. 14 (1994) 5147-5159
24. Dedio J., Konig P., Wohlfart P., Sschroeder C., Kummer W., and Muller-Esterl W. NOSIP, a novel modulator of endothelial nitric oxide synthase activity. FASEB J. 15 (2001) 79-89
25. DeWeerd W.F.C., and Leeb-Lundberg L.M.F. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled galpha subunits Galpha q and Galpha i in Caveolae in DDT1 MF-2 smooth muscle cells. J. Biol. Chem. 272 (1997) 17858-17866
26. Drexler H., Zeiher A.M., Meinzer K., and Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine. Lancet 338 (1991) 1546-1550
27. Elizalde M., Ryden M., van Harmelen V., Eneroth P., Gyllenhammar H., Holm C., Ramel S., Olund A., Arner P., and Andersson K. Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J. Lipid Res. 41 (2000) 1244-1251
28. Feron O., Smith T.W., Michel T., and Kelly R.A. Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes. J. Biol. Chem. 272 (1997) 17744-17748
29. Field A.E., Coakley E.H., Must A., Spadano J.L., Laird N., Dietz W.H., Rimm E., and Colditz G.A. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 161 (2001) 1581-1586
30. Fulton D., Gratton J.-P., and Sessa W.C. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?. J. Pharmacol. Exp. Ther. 299 (2001) 818-824
31. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
32. Garcia-Cardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A., and Sessa W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392 (1998) 821-824
33. Gaudiot N., Jaubert A.M., Charbonnier E., Sabourault D., Lacasa D., Giudicelli Y., and Ribiere C. Modulation of white adipose tissue lipolysis by nitric oxide. J. Biol. Chem. 273 (1998) 13475-13481
34. Gratton J.-P., Fontana J., O'Connor D.S., Garcia-Cardena G., McCabe T.J., and Sessa W.C. Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin-stimulated displacement of eNOS from calveolin-1. J. Biol. Chem. 275 (2000) 22268-22272
35. Griffith O.W., and Stuehr D.J. Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol. 57 (1995) 707-734
36. Gruetter C.A., Barry B.K., McNamara D.B., Gruetter D.Y., Kadowitz P.J., and Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J. Cyclic Nucleotide Res. 5 (1979) 211-224
37. Grundy S.M., Pasternak R., Greenland P., Smith Jr. S., and Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100 (1999) 1481-1492
38. Gryglewski R.J., Palmer R.M., and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320 (1986) 454-456
39. Health NIo. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes. Res. 6 Suppl 2 (1998) 51S-209S
40. Hevel J.M., White K.A., and Marletta M.A. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. J. Biol. Chem. 266 (1991) 22789-22791
41. Hibbs Jr. J.B., Taintor R.R., and Vavrin Z. Macrophage cytotoxicity: role for l-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235 (1987) 473-476
42. Hubert H., Feinleib M., McNamara P., and Castelli W. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67 (1983) 968-977
43. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 9265-9269
44. Ito T., Yasue H., Yoshimura M., Nakamura S., Nakayama M., Shimasaki Y., Harada E., Mizuno Y., Kawano H., and Ogawa H. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum. Genet. 110 (2002) 89-94
45. Joly G.A., Ayres M., and Kilbourn R.G. Potent inhibition of inducible nitric oxide synthase by geldanamycin, a tyrosine kinase inhibitor, in endothelial, smooth muscle cells, and in rat aorta. FEBS Lett. 403 (1997) 40-44
46. Ju H., Zou R., Venema V.J., and Venema R.C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 272 (1997) 18522-18525
47. Kannel W.B. Bishop lecture. Contribution of the Framingham Study to preventive cardiology. J. Am. Coll. Cardiol. 15 (1990) 206-211
48. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am. J. Hypertens. 13 (2000) 3S-10S
49. Katsuki S., Arnold W., Mittal C., and Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J. Cyclic Nucleotide Res. 3 (1977) 23-35
50. Khurana V.G., Feterik K., Springett M.J., Eguchi D., Shah V., and Katusic Z.S. Functional interdependence and colocalization of endothelial nitric oxide synthase and heat shock protein 90 in cerebral arteries. J. Cereb. Blood Flow Metab. 20 (2000) 1563-1570
51. Koshland Jr. D.E. The molecule of the year. Science 258 (1992) 1861
52. Langin D., Holm C., and Lafontan M. Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism. Proc. Nutr. Soc. 55 (1996) 93-109
53. Large V., Reynisdottir S., Langin D., Fredby K., Klannemark M., Holm C., and Arner P. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J. Lipid Res. 40 (1999) 2059-2066
54. Lerman A., Burnett Jr. J.C., Higano S.T., McKinley L.J., and Holmes Jr. D.R. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 97 (1998) 2123-2128
55. Marczin N., Antonov A., Papapetropoulos A., Munn D.H., Virmani R., Kolodgie F.D., Gerrity R., and Catravas J.D. Monocyte-induced downregulation of nitric oxide synthase in cultured aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1095-1103
56. Marletta M.A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78 (1994) 927-930
57. Marletta M.A., Yoon P.S., Iyengar R., Leaf C.D., and Wishnok J.S. Macrophage oxidation of l-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 27 (1988) 8706-8711
58. 2+-dependently converts l-arginine into an activator of soluble guanylyl cyclase. Biochem. Biophys. Res. Commun. 164 (1989) 678-685
59. Michel T., and Feron O. Nitric oxide synthases: which, where, how, and why?. J. Clin. Invest. 100 (1997) 2146-2152
60. 2+-calmodulin and caveolin. J. Biol. Chem. 272 (1997) 15583-15586
61. Michel J.B., Feron O., Sase K., Prabhakar P., and Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J. Biol. Chem. 272 (1997) 25907-25912
62. Minami Y., Kawasaki H., Suzuki K., and Yahara I. The calmodulin-binding domain of the mouse 90-kDa heat shock protein. J. Biol. Chem. 268 (1993) 9604-9610
63. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 329 (1993) 2002-2012
64. Nakayama M., Yasue H., Yoshimura M., Shimasaki Y., Kugiyama K., Ogawa H., Motoyama T., Saito Y., Ogawa Y., Miyamoto Y., and Nakao K. T-786 → C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99 (1999) 2864-2870
65. Nathan C., and Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell 78 (1994) 915-918
66. Nedvetsky P.I., Sessa W.C., and Schmidt H.H.H.W. There's NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling. PNAS 99 (2002) 16510-16512
67. Oike Y., Hata A., Ogata Y., Numata Y., Shido K., and Kondo K. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. J. Clin. Invest. 96 (1995) 2975-2979
68. Osawa Y., Lowe E.R., Everett A.C., Dunbar A.Y., and Billecke S.S. Proteolytic degradation of nitric oxide synthase: effect of inhibitors and role of hsp90-based chaperones. J. Pharmacol. Exp. Ther. 304 (2003) 493-497
69. Palmer R.M., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
70. Palmer R.M., Ashton D.S., and Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 333 (1988) 664-666
71. Pieper G.M. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol. 29 (1997) 8-15
72. Pieper G.M., and Peltier B.A. Amelioration by l-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J. Cardiovasc. Pharmacol. 25 (1995) 397-403
73. Pollock J.S., Forstermann U., Mitchell J.A., Warner T.D., Schmidt H.H., Nakane M., and Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10480-10484
74. Poulter N. Coronary heart disease is a multifactorial disease. Am. J. Hypertens. 12 (1999) 92S-95S
75. Pritchard Jr. K.A., Ackerman A.W., Gross E.R., Stepp D.W., Shi Y., Fontana J.T., Baker J.E., and Sessa W.C. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J. Biol. Chem. 276 (2001) 17621-17624
76. Puddu G.M., Cravero E., Arnone G., Muscari A., and Puddu P. Molecular aspects of atherogenesis: new insights and unsolved questions. J. Biomed. Sci. (2005) 1-15
77. Rector T.S., Bank A.J., Mullen K.A., Tschumperlin L.K., Sih R., Pillai K., and Kubo S.H. Randomized, double-blind, placebo-controlled study of supplemental oral l-arginine in patients with heart failure. Circulation 93 (1996) 2135-2141
78. Russell K.S., Haynes M.P., Caulin-Glaser T., Rosneck J., Sessa W.C., and Bender J.R. Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J. Biol. Chem. 275 (2000) 5026-5030
79. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. PNAS 97 (2000) 10832-10837
80. Shah V., Wiest R., Garcia-Cardena G., Cadelina G., Groszmann R.J., and Sessa W.C. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am. J. Physiol. 277 (1999) G463-G468
81. Sonel A.F., Good C.B., Mulgund J., Roe M.T., Gibler W.B., Smith Jr. S.C., Cohen M.G., Pollack Jr. C.V., Ohman E.M., and Peterson E.D. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines?). Circulation 111 (2005) 1225-1232
82. 2+/calmodulin binding. Biochem. J. 355 (2001) 357-360
83. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Luscher T., and Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99 (1997) 41-46
84. Stuehr D.J. Structure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 339-359
85. Stuehr D.J., and Marletta M.A. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J. Immunol. 139 (1987) 518-525
86. Stuehr D.J., Cho H.J., Kwon N.S., Weise M.F., and Nathan C.F. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7773-7777
87. Sugiishi M., and Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 87 (1993) 76-79
88. Venema R.C., Sayegh H.S., Arnal J.-F., and Harrison D.G. Role of the enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J. Biol. Chem. 270 (1995) 14705-14711
89. Venema R.C., Venema V.J., Ju H., Harris M.B., Snead C., Jilling T., Dimitropoulou C., Maragoudakis M.E., and Catravas J.D. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am. J. Physiol, Heart Circ. Physiol. 285 (2003) H669-H678
90. Viswanathan M., Rivera O., and Short B.L. Heat shock protein 90 is involved in pulsatile flow-induced dilation of rat middle cerebral artery. J. Vasc. Res. 36 (1999) 524-527
91. Yetik-Anacak G., Xia T., Dimitropoulou C., Venema R.C., and Catravas J.D. Effects of hsp90 binding inhibitors on sGC function. Am. J. Physiol, Heart Circ. Physiol. 291 (2006) H260-H268
92. Yoshida M., and Xia Y. Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J. Biol. Chem. 278 (2003) 36953-36958
93. Yoshimura M., Yasue H., Nakayama M., Shimasaki Y., Ogawa H., Kugiyama K., Saito Y., Miyamoto Y., Ogawa Y., Kaneshige T., Hiramatsu H., Yoshioka T., Kamitani S., Teraoka H., and Nakao K. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-786 → C and missense Glu298Asp variants. J. Investig. Med. 48 (2000) 367-374
94. Zeiher A.M., Schachinger V., and Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 92 (1995) 1094-1100
95. Zimmermann K., Opitz N., Dedio J., Renne C., Muller-Esterl W., and Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17167-17172